Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to characterise P. falciparum transmission intensity in subjects aged ≥6 months and <10 years by measurement of P. falciparum parasite prevalence, and to estimate the use of malaria control interventions at some centres selected for the EPI-MAL-002 and EPI-MAL-003 studies in sub-Saharan Western Africa.
Two subsequent studies (EPI-MAL-002 and EPI-MAL-003) are planned to monitor vaccine safety prior to and after implementation of the RTS,S/AS01 candidate malaria vaccine. EPI-MAL-002 will take place before RTS,S is authorised and EPI-MAL-003 will start when RTS,S is registered and authorised in the country. A cross-sectional survey at peak transmission will provide by-site point estimates of Parasite prevalence (PP) and malaria control measure coverage in the areas participating in EPI-MAL-002/-003. EPI-MAL-006 will be conducted in advance of EPI-MAL-002/-003 in order to assess PP and malaria control measures to inform enrollment in these studies. The age group for enrollment (≥6 months - <10 years) will permit analysis of PP according to the World Health Organization (WHO) definition (2-9 years) and by the Joint Technical Expert Group (JTEG) suggested age (<5 years).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Overall Study Group | Other | Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Capillary blood sample | Procedure | Capillary blood sample (up to 200µL) for determination of PP (blood slides). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), by Study Center | PFP = measurement of parasite prevalence (PP) by center according to joint technical expert group (JTEG). Centers: Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE), Naikhar (Dakar area)-Senegal (DA-2-SE). A subject was defined as infected by P. falciparum parasitemia, if at least two of the subject's blood slide readings were positive for the corresponding parasitemia.](streamdown:incomplete-link) | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Malaria Control Interventions (MCIs), Overall | MCI = measurement of residual spraying, mosquito net usage, seasonal malaria chemoprevention (SMC), intermittent preventative treatment in infants (IPTi) and Artemisinin-based combination therapy (ACT) - therapy received within the last 14 days as indicator of malaria transmission intensity (MTI) by center and JTEG according to P. Falciparum infection status. Centers: Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE), Naikhar (Dakar area)-Senegal (DA-2-SE). Results presented for overall centers by the following characteristics: Use of Mosquito colis over 7 days (UMc > 7D), Use of Insecticide spray over 7 days (UIs > 7D), Use of Commercial Repellents over 7 days (UCR > 7D), Use of Traditional Repellents over 7 days (UTR > 7D), Use of none of above over 7 days (Una >7D), Use of indoor residual spray in past 12 months to spray interior walls (Uirs past 12M), Use of indoor residual spray - number of months ago (Uirs-nM)](streamdown:incomplete-link) | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects Infected With P.Falciparum Parasitemia Receiving Malaria Control Interventions (MCIs), by Infection Status | MCI = measurement of residual spraying, mosquito net usage, seasonal malaria chemoprevention (SMC), intermittent preventative treatment in infants (IPTi) and Artemisinin-based combination therapy (ACT) - therapy received within the last 14 days as indicator of malaria transmission intensity (MTI) by center and JTEG according to P. Falciparum infection status. Centers: Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE), Naikhar (Dakar area)-Senegal (DA-2-SE). Results presented for overall centers by the following characteristics: Use of Mosquito colis over 7 days (UMc > 7D), Use of Insecticide spray over 7 days (UIs > 7D), Use of Commercial Repellents over 7 days (UCR > 7D), Use of Traditional Repellents over 7 days (UTR > 7D), Use of none of above over 7 days (Una >7D), Use of indoor residual spray in past 12 months to spray interior walls (Uirs past 12M), Use of indoor residual spray - number of months ago (Uirs-nM)](streamdown:incomplete-link) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects With Other Medical History Characteristics, Overall | The medical history characteristics were as follows: -subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated Bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS). | At Epoch 1 (Survey visit) (approximately 35 days) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Nouna | Burkina Faso | ||||
| GSK Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28166794 | Derived | Diallo A, Sie A, Sirima S, Sylla K, Ndiaye M, Bountogo M, Ouedraogo E, Tine R, Ndiaye A, Coulibaly B, Ouedraogo A, Faye B, Ba EH, Compaore G, Tiono A, Sokhna C, Ye M, Diarra A, Bahmanyar ER, De Boer M, Pircon JY, Usuf EA. An epidemiological study to assess Plasmodium falciparum parasite prevalence and malaria control measures in Burkina Faso and Senegal. Malar J. 2017 Feb 6;16(1):63. doi: 10.1186/s12936-017-1715-1. |
| Label | URL |
|---|---|
| Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research. | View source |
| ID | Type | URL | Comment |
|---|---|---|---|
| 200187 | Study Protocol | View IPD |
IPD is available via the Clinical Study Data Request site (click on the link provided below).
IPD is available via the Clinical Study Data Request site (click on the link provided below).
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Overall Study Group | Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Overall Study Group | Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), by Study Center | PFP = measurement of parasite prevalence (PP) by center according to joint technical expert group (JTEG). Centers: Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE), Naikhar (Dakar area)-Senegal (DA-2-SE). A subject was defined as infected by P. falciparum parasitemia, if at least two of the subject's blood slide readings were positive for the corresponding parasitemia.](streamdown:incomplete-link) | The According to Protocol (ATP) cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
Not provided
As planned per protocol, other (non-serious) adverse events were not collected.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Overall Study Group | Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D008288 | Malaria |
| ID | Term |
|---|---|
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D003625 | Data Collection |
| ID | Term |
|---|---|
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Data collection | Other | Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF) |
|
| At Epoch 1 (Survey visit) (approximately 35 days) |
| Odds Ratio (OR) for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Nouna Center in Burkina Faso | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only the reference category available for 'Use of Traditional Repellents over 7 days': Missing/No - There was only one category available for 'Use of indoor residual spray - number of month ago': 2 Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Numbers of days of malaria treatment (NdMt), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS), UMc > 7D, UIs > 7D, UCR > 7D, UTR > 7D, Una >7D, Uirs past 12M. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Ouagadougu Center in Burkina Faso | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only the reference category for 'Use of Insecticide spray over 7 days': Missing/No and 'Use of Traditional Repellents over 7 days': Missing/No - The reference category ('2') for 'Use of indoor residual spray - number of month ago': 2 Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Numbers of days of malaria treatment (NdMt), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS), UMc > 7D, UIs > 7D, UCR > 7D, UTR > 7D, Una >7D, Uirs past 12M. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Keur Soce Center in Dakar Area in Senegal | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only one category available for 'Exact number of days of malaria treatment':1-3 days, 'Use of Indoor residual spray - numbers of months ago': 9, 'Use of Commercial Repellents over 7 days': Missing/No - There were not enough values in the reference category ('<5') to compute the OR for HS. Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), UMc > 7D, UIs >7D, UCR > 7D, UTR > 7D, Una >7D. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Niakhar Center in Dakar Area in Senegal | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only one category available for 'Exact number of days of malaria treatment':1-3 days and 'How many holes of that size': ≥5. Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Numbers of days of malaria treatment (NdMt), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS), UMc > 7D, UIs > 7D, UCR > 7D, UTR > 7D, Una >7D, Uirs past 12M. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects by Age, According to P. Falciparum Infection Status | The annual age extended over a 0 year-9 years range. The age characteristics were summarized by P. falciparum infection status. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects by JTEG Age Group, According to P. Falciparum Infection Status | The JTEG categorisation referred to the distribution of subjects by different age groups: 6 months to 4 years of age inclusive (0.5Y-4Y category) and 5 to 9 years of age inclusive (5-9Y category), tabulated according to P. falciparum infection status. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects by Gender, According to P. Falciparum Infection Status | The gender characteristics were summarized by P. falciparum infection status. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Plasmodium Species Other Than P. Falciparum, by JTEG Age Group and Per Total Centers | Other Plasmodium species included: P. Malariae, P. Vivax, P. Ovale with Negative and Positive results. A subjects was defined as infected by a specified parasitemia if at least two of the subject's blood slide readings were positive for the corresponding parasitemia. The results were tabulated according to JTEG age categorisation. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Anti-malarial Therapy, Overall | Anti-malarial therapy included Malaria treatment (MT) in past 14 days, Other medication (OM) in past 14 days and Malaria hospitalization (MH) in the last 3 months. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Days With Therapy, Overall | The duration of anti-malarial therapy referred to the exact number of days of malaria treatment (EDMT) and the number of days of other medication (DOM). Note: * In case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Days of Malaria Treatment, Overall | This endpoint presents results per total centers and across all age categories. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Fever, Overall | Characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever* at visit (F* at V). Note: *Fever set to Yes if temperature recorded at visit after axillary conversion was ≥ 37.5 ◦C. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Days With Fever, Overall | This endpoint presents results per total centers and across all age categories. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Persons With P. Falciparum Living in the Same Part of the House of Persons Enrolled in the Study (PLSPH-PES), Overall | The malaria prevention and risk factor presented in this endpoint was: Number of persons living in the same part of the house - persons enrolled in the study (PLSPH-PES), in the following combinations: < y/x, where x are persons enrolled in the study among less than y persons living in the same part of the house, y-z/x, where x are persons enrolled in the study among y to z persons living in the same part of the house, > z/x, where x persons are enrolled in the study among more than z persons living in the same part of the house, y-z/> x, where more than x persons enrolled in the study among y to z persons living in the same part of the house, > z/> x, where more than x persons enrolled in the study among more than z persons living in the same part of the house. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Descriptive Statistics for Number of Persons With P. Falciparum Living in the Same Part of the House of Persons Enrolled in the Study (PLSPH-PES), Overall | The malaria prevention and risk factor presented in this endpoint was: Number of persons living in the same part of the house (PLSPH). | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Different P. Falciparum Parasite Densities, Living in the Same House, by Center | The malaria prevention and risk factor for this endpoint was: Number of subjects living in the same part of the house - persons enrolled in the study (PLSPH-PES), in the following combinations: < y/x, where x are persons enrolled in the study among less than y persons living in the same part of the house, y-z/x, where x are persons enrolled in the study among y to z persons living in the same part of the house, > z/x, where x persons are enrolled in the study among more than z persons living in the same part of the house, y-z/> x, where more than x persons enrolled in the study among y to z persons living in the same part of the house, > z/> x, where more than x persons enrolled in the study among more than z persons living in the same part of the house. Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | At Epoch 1 (Survey visit) (approximately 35 days) |
| Descriptive Statistics for Subjects With Different P. Falciparum Parasite Densities, Living in the Same House, by Center | The malaria prevention and risk factor for this endpoint was: Number of subjects living in the same part of the house (PLSPH). Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With P. Falciparum by Situation Area, Overall | The malaria prevention and risk factor characteristics for this endpoint were the following: Situation area (rural, urban, semi-rural) and Type of Location*. Note: *Large city = >1 million habitants; Small city = >50000 & < 1 million habitants ; Town = > 10000 and < 50000 habitants; Countryside = < 10000 habitants. | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Different P. Falciparum Densities by Situation Area and Center | The malaria prevention and risk factor characteristics were the following: Situation area (urban, rural, semi-rural) and Type of Location*. Note: *Large city = >1 million habitants; Small city = >50000 & < 1 million habitants ; Town = > 10000 and < 50000 habitants; Countryside = < 10000 habitants. Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With P. Falciparum by House Construction Material and Other House Information, Overall | The malaria prevention and risk factor characteristics for this endpoint were the following: - Main house construction material (MHCM) walls, floor, roof, windows/eaves, nets; - Main source of drinking water (MSDW); - Presence of electricity (PE). Note: *Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo. % Closed water source (piper water, tube well, dug well, protected well); Open water source (unprotected well, spring water, rainwater, tanker truck, surface water). | At Epoch 1 (Survey visit) (approximately 35 days) |
| Number of Subjects With Different P. Falciparum Parasite Densities, by House Information and Center | The malaria prevention and risk factor characteristics for this endpoint were the following: - Main house construction material (MHCM) walls, floor, roof, windows/eaves, nets; - Main source of drinking water (MSDW); - Presence of electricity (PE). Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo. Closed water source = pipe water, tube well, dug well, protected well; Open water source = unprotected well, spring water, rainwater, tanker truck, surface water. Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | At Epoch 1 (Survey visit) (approximately 35 days) |
| Ouagadougou |
| Burkina Faso |
| GSK Investigational Site | Dakar | Senegal |
For additional information about this study please refer to the GSK Clinical Study Register |
| 200187 | Clinical Study Report | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 200187 | Dataset Specification | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 200187 | Statistical Analysis Plan | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 200187 | Individual Participant Data Set | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| 200187 | Informed Consent Form | View IPD | For additional information about this study please refer to the GSK Clinical Study Register |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| OG001 | 5-9Y Group | Subjects aged 5 to 9 years (Y) old, who were infected or not infected with P. falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy. |
|
|
| Primary | Number of Subjects With Malaria Control Interventions (MCIs), Overall | MCI = measurement of residual spraying, mosquito net usage, seasonal malaria chemoprevention (SMC), intermittent preventative treatment in infants (IPTi) and Artemisinin-based combination therapy (ACT) - therapy received within the last 14 days as indicator of malaria transmission intensity (MTI) by center and JTEG according to P. Falciparum infection status. Centers: Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE), Naikhar (Dakar area)-Senegal (DA-2-SE). Results presented for overall centers by the following characteristics: Use of Mosquito colis over 7 days (UMc > 7D), Use of Insecticide spray over 7 days (UIs > 7D), Use of Commercial Repellents over 7 days (UCR > 7D), Use of Traditional Repellents over 7 days (UTR > 7D), Use of none of above over 7 days (Una >7D), Use of indoor residual spray in past 12 months to spray interior walls (Uirs past 12M), Use of indoor residual spray - number of months ago (Uirs-nM)](streamdown:incomplete-link) | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Primary | Number of Subjects Infected With P.Falciparum Parasitemia Receiving Malaria Control Interventions (MCIs), by Infection Status | MCI = measurement of residual spraying, mosquito net usage, seasonal malaria chemoprevention (SMC), intermittent preventative treatment in infants (IPTi) and Artemisinin-based combination therapy (ACT) - therapy received within the last 14 days as indicator of malaria transmission intensity (MTI) by center and JTEG according to P. Falciparum infection status. Centers: Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE), Naikhar (Dakar area)-Senegal (DA-2-SE). Results presented for overall centers by the following characteristics: Use of Mosquito colis over 7 days (UMc > 7D), Use of Insecticide spray over 7 days (UIs > 7D), Use of Commercial Repellents over 7 days (UCR > 7D), Use of Traditional Repellents over 7 days (UTR > 7D), Use of none of above over 7 days (Una >7D), Use of indoor residual spray in past 12 months to spray interior walls (Uirs past 12M), Use of indoor residual spray - number of months ago (Uirs-nM)](streamdown:incomplete-link) | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Primary | Odds Ratio (OR) for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Nouna Center in Burkina Faso | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only the reference category available for 'Use of Traditional Repellents over 7 days': Missing/No - There was only one category available for 'Use of indoor residual spray - number of month ago': 2 Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Numbers of days of malaria treatment (NdMt), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS), UMc > 7D, UIs > 7D, UCR > 7D, UTR > 7D, Una >7D, Uirs past 12M. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Number | 95% Confidence Interval | Unadjusted Odds Ratio | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Primary | Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Ouagadougu Center in Burkina Faso | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only the reference category for 'Use of Insecticide spray over 7 days': Missing/No and 'Use of Traditional Repellents over 7 days': Missing/No - The reference category ('2') for 'Use of indoor residual spray - number of month ago': 2 Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Numbers of days of malaria treatment (NdMt), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS), UMc > 7D, UIs > 7D, UCR > 7D, UTR > 7D, Una >7D, Uirs past 12M. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Number | 95% Confidence Interval | Unadjusted Odds Ratio | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Primary | Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Keur Soce Center in Dakar Area in Senegal | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only one category available for 'Exact number of days of malaria treatment':1-3 days, 'Use of Indoor residual spray - numbers of months ago': 9, 'Use of Commercial Repellents over 7 days': Missing/No - There were not enough values in the reference category ('<5') to compute the OR for HS. Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), UMc > 7D, UIs >7D, UCR > 7D, UTR > 7D, Una >7D. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Number | 95% Confidence Interval | Unadjusted Odds Ratio | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Primary | Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia, for the Niakhar Center in Dakar Area in Senegal | MCI = measurement of residual spraying, mosquito net usage, SMC, IPTi and ACT - therapy received within the last 14 days as indicator of MTI according to P. falciparum infection status. Note: - There was only one category available for 'Exact number of days of malaria treatment':1-3 days and 'How many holes of that size': ≥5. Characteristics were as follows: Malaria treatment in past 14 days (Mt past 14D), Numbers of days of malaria treatment (NdMt), Other medication in the past 14 days (Om past 14D), Number of days of other medication (Ndom), Was the subject hospitalized in the last 3 months due to Malaria (Wsh3MM), Subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS), UMc > 7D, UIs > 7D, UCR > 7D, UTR > 7D, Una >7D, Uirs past 12M. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Number | 95% Confidence Interval | Unadjusted Odds Ratio | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Other Medical History Characteristics, Overall | The medical history characteristics were as follows: -subject sleep under a mosquito net night before visit (Ssumnnbv), New net - less than 1 year (Nn < 1Y), Impregnated Bednet (Ib), Pierced/torn bednet (P/tb), How many holes of that size (HS). | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects by Age, According to P. Falciparum Infection Status | The annual age extended over a 0 year-9 years range. The age characteristics were summarized by P. falciparum infection status. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects by JTEG Age Group, According to P. Falciparum Infection Status | The JTEG categorisation referred to the distribution of subjects by different age groups: 6 months to 4 years of age inclusive (0.5Y-4Y category) and 5 to 9 years of age inclusive (5-9Y category), tabulated according to P. falciparum infection status. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects by Gender, According to P. Falciparum Infection Status | The gender characteristics were summarized by P. falciparum infection status. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Plasmodium Species Other Than P. Falciparum, by JTEG Age Group and Per Total Centers | Other Plasmodium species included: P. Malariae, P. Vivax, P. Ovale with Negative and Positive results. A subjects was defined as infected by a specified parasitemia if at least two of the subject's blood slide readings were positive for the corresponding parasitemia. The results were tabulated according to JTEG age categorisation. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Anti-malarial Therapy, Overall | Anti-malarial therapy included Malaria treatment (MT) in past 14 days, Other medication (OM) in past 14 days and Malaria hospitalization (MH) in the last 3 months. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Days With Therapy, Overall | The duration of anti-malarial therapy referred to the exact number of days of malaria treatment (EDMT) and the number of days of other medication (DOM). Note: * In case of several medication (malaria treatment or other medication) taken per subject, the maximum duration was computed for this study. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Number | Days | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Days of Malaria Treatment, Overall | This endpoint presents results per total centers and across all age categories. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Mean | Standard Deviation | Days | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Fever, Overall | Characteristics of fever were the following: Fever in the last 24 hours (F 24h) and Fever* at visit (F* at V). Note: *Fever set to Yes if temperature recorded at visit after axillary conversion was ≥ 37.5 ◦C. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Days With Fever, Overall | This endpoint presents results per total centers and across all age categories. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Mean | Standard Deviation | Days | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Persons With P. Falciparum Living in the Same Part of the House of Persons Enrolled in the Study (PLSPH-PES), Overall | The malaria prevention and risk factor presented in this endpoint was: Number of persons living in the same part of the house - persons enrolled in the study (PLSPH-PES), in the following combinations: < y/x, where x are persons enrolled in the study among less than y persons living in the same part of the house, y-z/x, where x are persons enrolled in the study among y to z persons living in the same part of the house, > z/x, where x persons are enrolled in the study among more than z persons living in the same part of the house, y-z/> x, where more than x persons enrolled in the study among y to z persons living in the same part of the house, > z/> x, where more than x persons enrolled in the study among more than z persons living in the same part of the house. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Descriptive Statistics for Number of Persons With P. Falciparum Living in the Same Part of the House of Persons Enrolled in the Study (PLSPH-PES), Overall | The malaria prevention and risk factor presented in this endpoint was: Number of persons living in the same part of the house (PLSPH). | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Mean | Standard Deviation | Persons Living in Same Part of House | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Different P. Falciparum Parasite Densities, Living in the Same House, by Center | The malaria prevention and risk factor for this endpoint was: Number of subjects living in the same part of the house - persons enrolled in the study (PLSPH-PES), in the following combinations: < y/x, where x are persons enrolled in the study among less than y persons living in the same part of the house, y-z/x, where x are persons enrolled in the study among y to z persons living in the same part of the house, > z/x, where x persons are enrolled in the study among more than z persons living in the same part of the house, y-z/> x, where more than x persons enrolled in the study among y to z persons living in the same part of the house, > z/> x, where more than x persons enrolled in the study among more than z persons living in the same part of the house. Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Descriptive Statistics for Subjects With Different P. Falciparum Parasite Densities, Living in the Same House, by Center | The malaria prevention and risk factor for this endpoint was: Number of subjects living in the same part of the house (PLSPH). Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Mean | Standard Deviation | Persons Living in Same Part of House | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With P. Falciparum by Situation Area, Overall | The malaria prevention and risk factor characteristics for this endpoint were the following: Situation area (rural, urban, semi-rural) and Type of Location*. Note: *Large city = >1 million habitants; Small city = >50000 & < 1 million habitants ; Town = > 10000 and < 50000 habitants; Countryside = < 10000 habitants. | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Different P. Falciparum Densities by Situation Area and Center | The malaria prevention and risk factor characteristics were the following: Situation area (urban, rural, semi-rural) and Type of Location*. Note: *Large city = >1 million habitants; Small city = >50000 & < 1 million habitants ; Town = > 10000 and < 50000 habitants; Countryside = < 10000 habitants. Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With P. Falciparum by House Construction Material and Other House Information, Overall | The malaria prevention and risk factor characteristics for this endpoint were the following: - Main house construction material (MHCM) walls, floor, roof, windows/eaves, nets; - Main source of drinking water (MSDW); - Presence of electricity (PE). Note: *Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo. % Closed water source (piper water, tube well, dug well, protected well); Open water source (unprotected well, spring water, rainwater, tanker truck, surface water). | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| Secondary | Number of Subjects With Different P. Falciparum Parasite Densities, by House Information and Center | The malaria prevention and risk factor characteristics for this endpoint were the following: - Main house construction material (MHCM) walls, floor, roof, windows/eaves, nets; - Main source of drinking water (MSDW); - Presence of electricity (PE). Natural floor = earth, sand, dung; Rudimentary floor = wood planks, palm, bamboo. Closed water source = pipe water, tube well, dug well, protected well; Open water source = unprotected well, spring water, rainwater, tanker truck, surface water. Results are presented for the Nouna-Burkina Faso (NOU-BF), Ouagadougou-Burkina Faso (OUA-BF), Keur Soce [Dakar area)-Senegal (DA-1-SE) and Naikhar (Dakar area)-Senegal (DA-2-SE) centers.](streamdown:incomplete-link) | The According to Protocol cohort included all evaluable subjects for whom at least one laboratory result of the blood sample was available. | Posted | Count of Participants | Participants | At Epoch 1 (Survey visit) (approximately 35 days) |
|
|
|
| 0 |
| 2,421 |
| 0 |
| 2,421 |
| 0 |
| 0 |
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D000079426 |
| Vector Borne Diseases |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
| Title | Measurements |
|---|---|
|
| UIs > 7D, Missing/No |
|
| UCR > 7D, Yes |
|
| UCR > 7D, Missing/No |
|
| UTR > 7D, Yes |
|
| UTR > 7D, Missing/No |
|
| Una >7D, Yes |
|
| Una >7D, Missing/No |
|
| Uirs past 12M, Yes |
|
| Uirs past 12M, Missing/No |
|
| Uirs-nM [1] |
|
| Uirs-nM [2] |
|
| Uirs-nM [3] |
|
| Uirs-nM [4] |
|
| Uirs-nM [5] |
|
| Uirs-nM [6] |
|
| Uirs-nM [7] |
|
| Uirs-nM [8] |
|
| Uirs-nM [9] |
|
| Uirs-nM [10] |
|
| Uirs-nM, Missing |
|
| Use of commercial repellents over 7 days |
|
| Use of traditional repellents over 7 days |
|
| Use of none of the above over 7 days |
|
| Use of indoor residual spray in past 12 months |
|
| Use of indoor residual spray in past 1 month |
|
| Use of indoor residual spray in past 2 months |
|
| Use of indoor residual spray in past 3 months |
|
| Use of indoor residual spray in past 4 months |
|
| Use of indoor residual spray in past 5 months |
|
| Use of indoor residual spray in past 6 months |
|
| Use of indoor residual spray in past 7 months |
|
| Use of indoor residual spray in past 8 months |
|
| Use of indoor residual spray in past 9 months |
|
| Use of indoor residual spray in past 10 months |
|
|
| OM PAST 14D, YES VS. NO |
|
| NDOM, 1-7 DAYS VS. ONGOING |
|
| NDOM, ≥8 DAYS VS. ONGOING |
|
| WSH3MM, YES VS. NO |
|
| SSUMNNBV, YES VS. NO |
|
| NN < 1Y, YES VS. NO |
|
| IB, YES VS. NO |
|
| P/TB, YES VS. NO |
|
| HS, ≥5 VS. <5 |
|
| UMC > 7D, YES VS. MISSING/NO |
|
| UIS > 7D, YES VS. MISSING/NO |
|
| UCR > 7D, YES VS. MISSING/NO |
|
| UNA >7D, YES VS. MISSING/NO |
|
| UIRS PAST 12M, YES VS. NO |
|
|
| OM PAST 14D, YES VS. NO |
|
| NDOM, 1-7 DAYS VS. ONGOING |
|
| NDOM, ≥8 DAYS VS. ONGOING |
|
| WSH3MM, YES VS. NO |
|
| SSUMNNBV, YES VS. NO |
|
| NN < 1Y, YES VS. NO |
|
| IB, YES VS. NO |
|
| P/TB, YES VS. NO |
|
| HS, ≥5 VS. <5 |
|
| UMC > 7D, YES VS. MISSING/NO |
|
| UIS > 7D, YES VS. MISSING/NO |
|
| UCR > 7D, YES VS. MISSING/NO |
|
| UTR > 7D, NOT PERFORMED |
|
| UNA >7D, YES VS. MISSING/NO |
|
| UIRS PAST 12M, YES VS. NO |
|
|
| NDOM, 1-7 days vs. Ongoing |
|
| WSH3MM, YES VS. NO |
|
| SSUMNNBV, YES VS. NO |
|
| NN < 1Y, YES VS. NO |
|
| IB, YES VS. NO |
|
| P/TB, YES VS. NO |
|
| UMC > 7D, YES VS. MISSING/NO |
|
| UIS > 7D, YES VS. MISSING/NO |
|
| UTR > 7D, YES VS. MISSING/NO |
|
| UNA >7D, YES VS. MISSING/NO |
|
| UIRS PAST 12M, YES VS. NO |
|
|
| NDOM, ≥8 DAYS VS. ONGOING |
|
| WSH3MM, YES VS. NO |
|
| SSUMNNBV, YES VS. NO |
|
| NN < 1Y, YES VS. NO |
|
| IB, YES VS. NO |
|
| P/TB, YES VS. NO |
|
| UMC > 7D, YES VS. MISSING/NO |
|
| UIS > 7D, YES VS. MISSING/NO |
|
| UCR > 7D, YES VS. MISSING/NO |
|
| UTR > 7D, Yes vs. Missing/NO |
|
| UNA >7D, YES VS. MISSING/NO |
|
| UIRS PAST 12M, YES VS. NO |
|
| Title | Measurements |
|---|---|
|
| NN < 1Y, NO |
|
| NN < 1Y, MISSING/NA |
|
| IB, YES |
|
| IB, NO |
|
| IB, MISSING/NA |
|
| P/TB, YES |
|
| P/TB, NO |
|
| P/TB, MISSING/NA |
|
| HS < 5 |
|
| HS ≥ 5 |
|
| HS, MISSING/NA |
|
| 2 year olds |
|
| 3 year olds |
|
| 4 year olds |
|
| 5 year olds |
|
| 6 year olds |
|
| 7 year olds |
|
| 8 year olds |
|
| 9 year olds |
|
| P. Vivax, Positive |
|
| P. Vivax, Negative |
|
| P. Ovale, Positive |
|
| P. Ovale, Negative |
|
| Title | Measurements |
|---|---|
|
| OM IN PAST 14 DAYS, NO |
|
| MH IN THE LAST 3 MONTHS, YES |
|
| MH IN THE LAST 3 MONTHS, NO |
|
| Title | Measurements |
|---|---|
|
| EDMT, Missing/NA |
|
| DOM, Ongoing |
|
| DOM, 1-7 days |
|
| DOM, ≥ 8 days |
|
| DOM, Missing/NA |
|
| Title | Measurements |
|---|---|
|
| F* at V, No |
|
| F* at V, Missing |
|
| Title | Measurements |
|---|---|
|
| PLSPH-PES, <3/2 |
|
| PLSPH-PES, 4-5/2 |
|
| PLSPH-PES, >5/2 |
|
| PLSPH-PES, <3/3 |
|
| PLSPH-PES, 4-5/3 |
|
| PLSPH-PES, >5/3 |
|
| PLSPH-PES, 4-5/>3 |
|
| PLSPH-PES, >5/>3 |
|
| NOU-BF, PLSP-PES, 4-5/1 |
|
| NOU-BF, PLSP-PES, >5/1 |
|
| NOU-BF, PLSP-PES, <3/2 |
|
| NOU-BF, PLSP-PES, 4-5/2 |
|
| NOU-BF, PLSP-PES, >5/2 |
|
| NOU-BF, PLSP-PES, <3/3 |
|
| NOU-BF, PLSP-PES, 4-5/3 |
|
| NOU-BF, PLSP-PES, >5/3 |
|
| NOU-BF, PLSP-PES, 4-5/>3 |
|
| NOU-BF, PLSP-PES, >5/>3 |
|
| OUA-BF, PLSP-PES, <3/1 |
|
| OUA-BF, PLSP-PES, 4-5/1 |
|
| OUA-BF, PLSP-PES, >5/1 |
|
| OUA-BF, PLSP-PES, <3/2 |
|
| OUA-BF, PLSP-PES, 4-5/2 |
|
| OUA-BF, PLSP-PES, >5/2 |
|
| OUA-BF, PLSP-PES, <3/3 |
|
| OUA-BF, PLSP-PES, 4-5/3 |
|
| OUA-BF, PLSP-PES, >5/3 |
|
| OUA-BF, PLSP-PES, 4-5/>3 |
|
| OUA-BF, PLSP-PES, >5/>3 |
|
| DA-1-SE, PLSP-PES, <3/1 |
|
| DA-1-SE, PLSP-PES, 4-5/1 |
|
| DA-1-SE, PLSP-PES, >5/1 |
|
| DA-1-SE, PLSP-PES, <3/2 |
|
| DA-1-SE, PLSP-PES, 4-5/2 |
|
| DA-1-SE, PLSP-PES, >5/2 |
|
| DA-1-SE, PLSP-PES, <3/3 |
|
| DA-1-SE, PLSP-PES, 4-5/3 |
|
| DA-1-SE, PLSP-PES, >5/3 |
|
| DA-1-SE, PLSP-PES, 4-5/>3 |
|
| DA-1-SE, PLSP-PES, >5/>3 |
|
| DA-2-SE, PLSP-PES, <3/1 |
|
| DA-2-SE, PLSP-PES, 4-5/1 |
|
| DA-2-SE, PLSP-PES, >5/1 |
|
| DA-2-SE, PLSP-PES, <3/2 |
|
| DA-2-SE, PLSP-PES, 4-5/2 |
|
| DA-2-SE, PLSP-PES, >5/2 |
|
| DA-2-SE, PLSP-PES, <3/3 |
|
| DA-2-SE, PLSP-PES, 4-5/3 |
|
| DA-2-SE, PLSP-PES, >5/3 |
|
| DA-2-SE, PLSP-PES, 4-5/>3 |
|
| DA-2-SE, PLSP-PES, >5/>3 |
|
| OUA-BF, PLSPH |
|
| DA-1-SE, PLSPH |
|
| DA-2-SE, PLSPH |
|
| Title | Measurements |
|---|---|
|
| Type of Location, Large city |
|
| Type of Location, Small city |
|
| Type of Location, Town |
|
| Type of Location, Countryside |
|
| NOU-BF, Situation area, Urban |
|
| NOU-BF, Situation area, semi-rural |
|
| NOU-BF, Type of Location, Large city |
|
| NOU-BF, Type of Location, Small city |
|
| NOU-BF, Type of Location, Town |
|
| NOU-BF, Type of Location, Countryside |
|
| OUA-BF, Situation area, Rural |
|
| OUA-BF, Situation area, Urban |
|
| OUA-BF, Situation area, semi-rural |
|
| OUA-BF, Type of Location, Large city |
|
| OUA-BF, Type of Location, Small city |
|
| OUA-BF, Type of Location, Town |
|
| OUA-BF, Type of Location, Countryside |
|
| DA-1-SE, Situation area, Rural |
|
| DA-1-SE, Situation area, Urban |
|
| DA-1-SE, Situation area, semi-rural |
|
| DA-1-SE, Type of Location, Large city |
|
| DA-1-SE, Type of Location, Small city |
|
| DA-1-SE, Type of Location, Town |
|
| DA-1-SE, Type of Location, Countryside |
|
| DA-2-SE, Situation area, Rural |
|
| DA-2-SE, Situation area, Urban |
|
| DA-2-SE, Situation area, semi-rural |
|
| DA-2-SE, Type of Location, Large city |
|
| DA-2-SE, Type of Location, Small city |
|
| DA-2-SE, Type of Location, Town |
|
| DA-2-SE, Type of Location, Countryside |
|
| Title | Measurements |
|---|---|
|
| MHCM walls, cement/paint |
|
| MHCM walls, other |
|
| MHCM floor, natural floor* |
|
| MHCM floor, rudimentary floor* |
|
| MHCM floor, vinyl oe asphalt strips |
|
| MHCM floor, ceramic tiles |
|
| MHCM floor, cement |
|
| MHCM floor, carpet |
|
| MHCM floor, other |
|
| MHCM roof, glass/palm |
|
| MHCM roof, iron sheet |
|
| MHCM roof, tiles |
|
| MHCM roof, missing |
|
| MHCM windows/eaves, closed |
|
| MHCM windows/eaves, open |
|
| MHCM windows/eaves, partially open |
|
| MHCM windows/eaves, missing |
|
| MHCM nets, not present |
|
| MHCM nets, present on all windows |
|
| MHCM nets, present on some windows |
|
| MHCM nets, missing |
|
| MSDW, bottled water |
|
| MSDW, closed water source % |
|
| MSDW, open water source % |
|
| MSDW, not applicable |
|
| PE, Yes |
|
| PE, No |
|
| MHCM walls, mud : OUA-BF |
|
| MHCM walls, mud : DA-1-SE |
|
| MHCM walls, mud : DA-2-SE |
|
| MHCM walls, brick : NOU-BF |
|
| MHCM walls, brick : OUA-BF |
|
| MHCM walls, brick : DA-1-SE |
|
| MHCM walls, brick : DA-2-SE |
|
| MHCM walls, cement/plaster : NOU-BF |
|
| MHCM walls, cement/plaster : OUA-BF |
|
| MHCM walls, cement/plaster : DA-1-SE |
|
| MHCM walls, cement/plaster : DA-2-SE |
|
| MHCM walls, cement/paint : NOU-BF |
|
| MHCM walls, cement/paint : OUA-BF |
|
| MHCM walls, cement/paint : DA-1-SE |
|
| MHCM walls, cement/paint : DA-2-SE |
|
| MHCM walls, other : NOU-BF |
|
| MHCM walls, other : OUA-BF |
|
| MHCM walls, other : DA-1-SE |
|
| MHCM walls, other : DA-2-SE |
|
| MHCM floor, natural floor : NOU-BF |
|
| MHCM floor, natural floor : OUA-BF |
|
| MHCM floor, natural floor : DA-1-SE |
|
| MHCM floor, natural floor : DA-2-SE |
|
| MHCM floor, rudimentary floor : NOU-BF |
|
| MHCM floor, rudimentary floor : OUA-BF |
|
| MHCM floor, rudimentary floor : DA-1-SE |
|
| MHCM floor, rudimentary floor : DA-2-SE |
|
| MHCM floor, vinyl or asphalt strips : NOU-BF |
|
| MHCM floor, vinyl or asphalt strips : OUA-BF |
|
| MHCM floor, vinyl or asphalt strips : DA-1-SE |
|
| MHCM floor, vinyl or asphalt strips : DA-2-SE |
|
| MHCM floor, ceramic tiles : NOU-BF |
|
| MHCM floor, ceramic tiles : OUA-BF |
|
| MHCM floor, ceramic tiles : DA-1-SE |
|
| MHCM floor, ceramic tiles : DA-2-SE |
|
| MHCM floor, cement : NOU-BF |
|
| MHCM floor, cement : OUA-BF |
|
| MHCM floor, cement : DA-1-SE |
|
| MHCM floor, cement : DA-2-SE |
|
| MHCM floor, carpet : NOU-BF |
|
| MHCM floor, carpet : OUA-BF |
|
| MHCM floor, carpet : DA-1-SE |
|
| MHCM floor, carpet : DA-2-SE |
|
| MHCM floor, other : NOU-BF |
|
| MHCM floor, other : OUA-BF |
|
| MHCM floor, other : DA-1-SE |
|
| MHCM floor, other : DA-2-SE |
|
| MHCM roof, glass/palm : NOU-BF |
|
| MHCM roof, glass/palm : OUA-BF |
|
| MHCM roof, glass/palm : DA-1-SE |
|
| MHCM roof, glass/palm : DA-2-SE |
|
| MHCM roof, iron sheet : NOU-BF |
|
| MHCM roof, iron sheet : OUA-BF |
|
| MHCM roof, iron sheet : DA-1-SE |
|
| MHCM roof, iron sheet : DA-2-SE |
|
| MHCM roof, tiles : NOU-BF |
|
| MHCM roof, tiles : OUA-BF |
|
| MHCM roof, tiles : DA-1-SE |
|
| MHCM roof, tiles : DA-2-SE |
|
| MHCM windows/eaves, closed : NOU-BF |
|
| MHCM windows/eaves, closed : OUA-BF |
|
| MHCM windows/eaves, closed : DA-1-SE |
|
| MHCM windows/eaves, closed : DA-2-SE |
|
| MHCM windows/eaves, open : NOU-BF |
|
| MHCM windows/eaves, open : OUA-BF |
|
| MHCM windows/eaves, open : DA-1-SE |
|
| MHCM windows/eaves, open : DA-2-SE |
|
| MHCM windows/eaves, partially open : NOU-BF |
|
| MHCM windows/eaves, partially open : OUA-BF |
|
| MHCM windows/eaves, partially open : DA-1-SE |
|
| MHCM windows/eaves, partially open : DA-2-SE |
|
| MHCM nets, not present : NOU-BF |
|
| MHCM nets, not present : OUA-BF |
|
| MHCM nets, not present : DA-1-SE |
|
| MHCM nets, not present : DA-2-SE |
|
| MHCM nets, present on all windows : NOU-BF |
|
| MHCM nets, present on all windows : OUA-BF |
|
| MHCM nets, present on all windows : DA-1-SE |
|
| MHCM nets, present on all windows : DA-2-SE |
|
| MHCM nets, present on some windows : NOU-BF |
|
| MHCM nets, present on some windows : OUA-BF |
|
| MHCM nets, present on some windows : DA-1-SE |
|
| MHCM nets, present on some windows : DA-2-SE |
|
| MSDW, bottled water : NOU-BF |
|
| MSDW, bottled water : OUA-BF |
|
| MSDW, bottled water : DA-1-SE |
|
| MSDW, bottled water : DA-2-SE |
|
| MSDW, closed water source : NOU-BF |
|
| MSDW, closed water source : OUA-BF |
|
| MSDW, closed water source : DA-1-SE |
|
| MSDW, closed water source : DA-2-SE |
|
| MSDW, open water source : NOU-BF |
|
| MSDW, open water source : OUA-BF |
|
| MSDW, open water source : DA-1-SE |
|
| MSDW, open water source : DA-2-SE |
|
| MSDW, not applicable : NOU-BF |
|
| MSDW, not applicable : OUA-BF |
|
| MSDW, not applicable : DA-1-SE |
|
| MSDW, not applicable : DA-2-SE |
|
| PE, Yes : NOU-BF |
|
| PE, Yes : OUA-BF |
|
| PE, Yes : DA-1-SE |
|
| PE, Yes : DA-2-SE |
|
| PE, No : NOU-BF |
|
| PE, No : OUA-BF |
|
| PE, No : DA-1-SE |
|
| PE, No : DA-2-SE |
|